Overall, this study underscores an advancement in targeted BNCT, highlighting B‐Glc as an effective GLUT1‐targeting carrier for enhanced therapeutic outcome in HNSCC and the potential to use [18F]FDG as a companion diagnostic for the glucoconjugate. The gene discussed is SLC2A1; the disease is head and neck squamous cell carcinoma.